中医药方剂在晚期肝癌患者疼痛减轻和生存期延长方面的作用

发布时间：2018-01-17 14:02

本文关键词：中医药方剂在晚期肝癌患者疼痛减轻和生存期延长方面的作用　出处：《辽宁中医杂志》2017年10期 　论文类型：期刊论文

【摘要】：目的:探讨中医药方剂的运用在晚期肝癌患者疼痛减轻和生存期延长方面的作用。方法:选取89例晚期肝癌患者,按照病人治疗意愿分成两组,对照组35例,观察组54例;对照组予以止痛等减症支持治疗,观察组在对照组的基础上予以中医药方剂辨证治疗;患者疼痛情况主要以患者主观感受和疼痛视觉模拟(VAS)评估,分别记录两组患者给药前、后VAS评分和患者肝功能指标及1月、2月、3月生存率。结果:两组患者治疗后疼痛均有显著减轻(P0.05),但观察组治疗后第1月时VAS评分为(5.7±1.2)显著低于对照组,P0.05,差异显著,具有统计学意义;统计两组生存率及生存时间,观察组在1月、2月、3月时的生存率分别是88.89%、75.95%、66.67%均显著高于对照组,P0.05,差异具有统计学意义;比较治疗前、后1个月时两组患者部分肝功能指标(ALT、AST、Tb)及甲胎蛋白(AFP),治疗后两组指标均有下降,观察组ALT(93.2±11.5)U/L、AST(96.5±13.8)U/L、Tb(54.3±4.7)μmol/L、AFP(705±203)μg/L均低于对照组,P0.05,差异显著,具有统计学意义。结论:中医药方剂可有效减轻肝癌晚期患者的疼痛,普遍延长生存期。
[Abstract]:Objective: to explore the effect of traditional Chinese medicine (TCM) on pain relief and survival time prolongation in patients with advanced liver cancer. Methods: 89 patients with advanced liver cancer were divided into two groups according to their intention to treat. 35 cases in control group and 54 cases in observation group; The control group was treated with pain relief and other symptomatic support therapy, while the observation group was treated with TCM prescription differentiation on the basis of the control group. The patients' pain was assessed by subjective feeling and visual analogue of pain. The VAS score and liver function were recorded before and after administration of the drug, January, February, respectively. Results: after treatment, the pain in both groups was significantly alleviated (P 0.05), but the VAS score in the observation group was significantly lower than that in the control group on January (5. 7 卤1. 2). P0.05, the difference is significant, has the statistical significance; The survival rate and survival time of the two groups were 88.89 on January, February and March, respectively, and 66.67% of the two groups were significantly higher than the control group (P0.05). The difference is statistically significant. Before and one month after treatment, some liver function indexes of the two groups were compared with alt ASTT Tb) and AFP, and the indexes of both groups were decreased after treatment. In the observation group, the ALT(93.2 卤11.5U / L ~ (-1) / L ~ (-1) / L ~ (-1) T _ (1) / L ~ (1) T _ (3) / L ~ (-1) T _ (B) was 54.3 卤4.7 渭 mol/L. AFP(705 卤203 渭 g / L was significantly lower than that of control group (P 0.05). Conclusion: TCM prescription can effectively relieve pain in patients with advanced liver cancer. The survival period is generally prolonged.
【作者单位】：河北省中医院脾胃病二科;河北医科大学研究生学院;河北中医学院研究生学院;
【基金】：河北省中医药管理局科研计划项目(2014171)
【分类号】：R273
【正文快照】： 原发性肝癌(primary liver cancer,PLC)是发生在肝细胞或肝内胆管细胞的恶性肿瘤(区别于继发性肝癌),在我国是十分常见的恶性肿瘤之一,预后极差,自然生存期仅2~6个月[1],死亡率在消化道肿瘤中排在胃癌和食管癌之后,位居第三。PLC可发生于任何年龄,40~49岁是高发年龄,男女比例

【相似文献】